Editorial Perspective—Advances in B-Cell Non-Hodgkin's Lymphoma

References

• Harris, N.L. (1997) "Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group)", Ann. Oncol., 8(Suppl 2), 11 — 16.
   Google Scholar
• Fisher, RI., Miller, T.P. and Grogan, T.M. (1998) "New REAL clinical entities", Cancer J. Sci. Am., 4(Suppl 2), S5—S12.
   Google Scholar
• Jaffe, E.S., Harris, N.L., Diebold, J. and Muller-Hermelink, H.K. (1999) "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report", Am. J. Clin. Pathol., 111, S8 —S12.
   Web of Science ®Google Scholar
• Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, RI., et al. (2002) "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lympho-ma", N. Engl. J. Med., 346, 1937–1947.
   Web of Science ®Google Scholar
• Coiffier, B. (2002) "Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lympho-ma", Semin. Oncol., 29, 18–22.
   Google Scholar
• Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., etal. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N. Engl. J. Med., 346, 235–242.
   PubMed Web of Science ®Google Scholar
• Seymour, J.F., Grigg, A.P., Szer, J. and Fox, R.M. (2001) "Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders", Ann. Oncol., 12, 1455 — 1460.
   Google Scholar
• McLaughlin, P., Hagemeister, F.B., Rodriguez, MA., Sarris, A.H., Pate, 0., Younes, A., et al. (2000) "Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma", Semin. Oncol., 27, 37 — 41.
   Google Scholar
• Zinzani, P.L., Magagnoli, M., Bendandi, M., Gherlinzoni, F., Orcioni, G.F., Cellini, C., et al. (2000) "Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas", Ann. Oncol., 11, 363–365.
   Google Scholar
• Bosch, F., Ferrer, A., Lopez-Guillermo, A., Gine, E., Bellosillo, B., Villamor, N., et al. (2002) "Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia", Br. J. Haematol., 119, 976–984.
   PubMed Web of Science ®Google Scholar
• Crawley, CR., Foran, J.M., Gupta, R.K., Rohatiner, AZ., Summers, K., Matthews, J., et al. (2000) "A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma", Ann. Oncol., 11, 861–865.
   Google Scholar
• Zinzani P.L. on behalf of an Italian Cooperative Study Group on Lymphoma (2002) "A randomised trial of fludarabine versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma", Ann. Oncol., 13\(Suppl 2), 57 (Abstract 185).
   Google Scholar
• Cazin, B., Maloum, K., Divine, M., Lepretre, S., Travade, P., Delmer, A., et al. (2002) "Oral fludarabine and cyclophosphamide in previously untreated CLL: Preliminary data on 75 pts", Blood, 100, 206a (Abstract 773).
   Google Scholar
• Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., et al. (2002) "Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritux-imab-refractory follicular non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3262 — 3269.
   Web of Science ®Google Scholar
• Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., etal. (2002) "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunother-apy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodg-kin's lymphoma", J. Clin. Oncol., 20, 2453–2463.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S., Estes, J., Zasadny, KR., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) "Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96, 1259–1266.
   Google Scholar
• Kaminski, M.S., Zelenetz, A.D., Press, 0.W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) "Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or trans-formed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 19, 3918 — 3928.
   Google Scholar
• Press, 0.W., Eary, J.F., Appelbaum, FR., Martin, P.J., Badger, CC., Nelp, W.B., et al. (1993) "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support", N. Engl. J. Med., 329, 1219–1224.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S., Tuck, M., Regan, D., Kison, P. and Wahl, R.L. (2002) "High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine tositumomab (Bexxar)", Blood, 100, 356a1–131 (Abstract 1381).
   Google Scholar
• Leonard, J., Coleman, M., Kostakoglu, L., Morris, A., Gregory, S., Link, B., et al. (2001) "BexxarTM (iodine tositumomab and tositumomab) can be administered safely in sequential combination with chemotherapy in initial treatment of non-Hodgkins lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 20, 287a 1–131(Abstract 1146).
   Google Scholar
• Emmanouilides, C., Witzig, T., Molina, A., Gordon, L., Multani, P., Wiseman, G., et al. (2003) "Improved safety and efficacy of Y-90-ibritumomab tiuxetan (Zevalin) radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low grade, follicular and transformed B-cell non-Hodgkin's lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 22, 595 (Abstract 2392).
   Google Scholar
• Gordon, L.I., Witzig, T.E., Emmanouilides, C., Raubitschek, A., Spies, S., Wiseman, G., et al. (2002) "90Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity", Proc. Am. Soc. Clin. Oncol., 21, 266a (Abstract 1061).
   Google Scholar
• Bartlett, N.L., Witzig, T.E., Gordon, L., Beck, T., Fehrenbacher, L., Kornmehl, E., etal. (2002) "90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lym-phoma (NHL) patients", Proc. Am. Soc. Clin. Oncol., 21, 14a (Abstract 51).
   Google Scholar